When it comes to identifying target stocks for investment, compelling prospects may include companies that are undervalued and, simultaneously, expected to appreciate in the future.
NEW YORK , Sept. 11, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of DexCom, Inc. (NASDAQ: DXCM)  breached their fi
DexCom, Inc. (NASDAQ:DXCM ) Baird Global Healthcare Conference 2025 September 10, 2025 2:00 PM EDT Company Participants Sean Christensen - Vice President of Finance and Investor Relations Conference C
SAN DIEGO & BURNABY, British Columbia--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the launch of its first open call in the U.S. and Canada i
DexCom, Inc. (NASDAQ:DXCM ) 2025 Wells Fargo Healthcare Conference September 3, 2025 2:15 PM EDT Company Participants Jacob Leach - President & COO Jereme Sylvain - Executive VP, CFO & Chief Accountin
AbbVie, Amgen, Stryker and Dexcom are tapping into the booming silver economy with new therapies, tech and acquisitions aimed at aging populations.
DexCom (DXCM) reported earnings 30 days ago. What's next for the stock?
Shares of DexCom (DXCM 0.02%), a medical device specialist, have lagged the market this year. However, the true test of a company isn't how it performs over a relatively short period, such as eight mo
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming investor conferences: The 2025 Wells Fargo Health
DXCM grows on type 2 access, Stelo adoption, and new sensor launches, but faces margin pressures, competition and leadership transition.

2 Stocks to Buy on the Dip and Hold for 10 Years

05:30am, Saturday, 16'th Aug 2025
Despite President Donald Trump's trade wars and concerns about a possible recession, equity markets have performed relatively well this year, with the S&P 500 (^GSPC -0.29%) up 10% since January. Some
NEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against DexCom, Inc. (NASDAQ: DXCM) on b
CNBC's "The Exchange" team discusses the potential of tariffs on pharmaceuticals, U.S. manufacturing and more with Dexcom CEO and chairman Kevin Sayer.

DexCom (DXCM) Q2 Revenue Jumps 15%

12:53am, Friday, 01'st Aug 2025
DexCom (DXCM) Q2 Revenue Jumps 15%
DXCM beats on Q2 earnings and raises 2025 sales guidance, but shares dip as margin pressure dampens investor enthusiasm.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE